CUL3 mutations are less common than those in other KEAP1‐NRF2‐pathway components, and the effect of triple mutations including CUL3 on clinical outcomes of patients with EGFR‐mutant NSCLC is unclear. The gene discussed is CUL3; the disease is non-small cell lung carcinoma.